INTRODUCTION
Human platelets have a predominantly aerobic glycolytic metabolism (1, 2) . They contain considerable glycogen Dr. Karpatkin is a Career Scientist of the Health Research Council of the City of New York (I-459).
Received for publication 2 July 1969 and in revised form 18 August 1969. stores, equivalent to those of skeletal muscle (1, 3) . Glycogenolysis in human platelets represents approximately 50% of glycolytic flux through the EmbdenMeyerhof pathway in the presence of physiologic concentrations of glucose (1, 3) . Human platelets contain a glycogen degradative enzyme, phosphorylase, which is similar in some respects to that of skeletal muscle (4) but different in other respects (5) .
This investigation was designed to determine whether glycogen synthesis takes place in human platelets and whether the "gluconeogenic" pathway was present, i.e., conversion of pyruvate and citrate to glucose or glycogen. Isotopic labeling techniques were employed to measure incorporation of precursor into glycogen. The extent of glycogen labeling was determined by techniques which employed the isolation of previously labeled platelet glycogen during intervals of glycogen synthesis and glycogen degradation. The isolated platelet glycogen was then analyzed for 1-4 glucosyl linkages by specific enzymatic degradation.
METHODS
Fresh human platelets were obtained, washed, processed, and incubated at 370C as described previously (1, 3, 6 ).
All materials were obtained from vendors as described previously (1, 3, 6) . Uniformly labeled glucose-1'C, 261 mc/ mmole, citrate-14C labeled in the 1-5 position, 1 followed by two alcohol precipitations. Glycogen was assayed with anthrone reagent as described previously (3, 6) . Glycogen molarity is expressed as glucose units. The labeled glycogen was dissolved in 1 ml of distilled water and an aliquot pipetted into a glass counting vial containing Bray's solution (7) . Radioactivity was determined in a Beckman LS100 scintillation spectrometer with isoset adjusted to give 96% counting efficiency. The radioactivity in the glycogen samples was 60 times background after incubating platelets with glucose-"C, 20 times background with pyruvate-14C, and 6-7 times background in citrate-"C experiments. The counting error was less than 3%. Control experiments revealed that addition of unlabeled platelet glycogen samples did not reduce the counting efficiency of a standard quantity of radioactivity. The concentration of tissue sample employed for radioactivity measurements was well within the equal linear range of sample concentration addition vs. radioactivity obtained. Briefly, 100 ,ug of f8-amylase was incubated with 1 mg of platelet glycogen in 1 ml of NaAc buffer, 16 mmoles/liter, pH 4.8 for 14 hr at 250C. These incubation conditions were found to be optimum. In control samples, ft-amylase was replaced by a comparable volume of buffer. The glycogen samples were then precipitated and redissolved. The difference in radioactivity and glycogen content between control and enzyme digested samples represented the 1-4 linked tier of branched glycogen beyond the 1-6 glucosyl linkage. The limit dextrin obtained could be hydrolyzed to less than 5% of original radioactivity, as well as glycogen content, by incubation with phosphorylase and amylo-1,6-glucosidase for 20 hr at 250C. Glycogen synthetase was measured by a radioisotopic procedure which was essentially a modification of the procedure of Villar-Palasi and Larner (9) . The platelet pellet was frozen in liquid nitrogen, ground in sand to a fine powder, and extracted in three times its volume of 50 mM Tris buffer, pH 8.2 containing 5 mM ethylenediaminetetraacetate(EDTA) and 5 mm MSH. The optimal concentration of MSH found to produce maximal enzyme activity was 5 mmoles/liter. The extract was centrifuged at 4000 g at 40C and the supernatant employed for glycogen synthetase determination. The preparation was stable at 4°C for at least 1 wk. A 0.1 ml aliquot was added to 0.4 ml of enzyme incubation solution at 37°C for 15 min containing (final concentration): UDPG-14C, 1 x 10. cpm/ml (varying concentration of unlabeled UDPG), 0.5 g/100 ml glycogen, 5 mM MSH, 5 mm EDTA, 50 mm Tris buffer, pH 8.2, and varying concentration of glucose-6-phosphate. The incubation was terminated by the addition of 33% KOH, the glycogen extracted, and radioactivity assayed as described above. The reaction was linear with time and enzyme extract concentration. Control experiments revealed negligible adsorption of UDPG-'4C to glycogen in the glycogen isolation procedure. All counts were at least 100 times background and counting error was less than 0.5%o.
An enzyme with fructose-1,6-diphosphatase activity was prepared from a frozen platelet pellet treated as above for glycogen synthetase but extracted in three times its volume of 50 mm Tris buffer, pH 7.5, and 20 mm MSH. The extract was similarly centrifuged and enzyme activity of the supernatant measured. Further purification of this enzyme was obtained by extraction in 40 mg/ml charcoal (Norite A), followed by centrifugation at 105,000 g for 60 min at 40C. The supernatant was treated with crystalline (NH4)2 SO0 at 4VC, which served to precipitate the enzyme at the 24-32 g/100 ml fraction. This resulted in a 20-fold purification and 10%o yield from the 4000 g platelet extract supernatant. The specific activity of this preparation at pH 7.5, 30'C was 1 /smole fructose 6-phosphate/min per mg protein. This preparation was stable for several hours at 0C, losing variable degrees of activity after storage overnight at 4GC. The final assay cuvette concentration contained 50-100 ,L/ ml platelet extract, 0.46 mm NADP, 0.1-2 mm fructose-1,6-diphosphate, 4 Aeg/ml glucose 6-phosphate dehydrogenase, 16 jig/ml hexose isomerase, and 20 mm MSH, in 50 mM Tris buffer, pH 7.5 (10). For orthophosphate release experiments, an assay was employed which was described previously (3). In view of the glycogen synthesis data of Figs. 1 and 2, it seemed likely that higher glycogen synthesis took place in association with higher platelet glycogen levels. This in turn strongly suggested that platelet glycogen was acting as a primer for further glucosyl unit deposition on outer tiers of preexistent glycogen branches.
Examination of platelet glycogen prelabeled with glucose-'C' during glycogen synthesis. Platelets were incubated in human Ringer's solution with glucose-UC 1 Because of the requirement of prohibitive quantities of radioisotopes for the incubation of significant numbers of platelets at physiologic platelet concentrations, all further experiments were performed with platelet suspensions of 5%. As will be noted, the information desired did not require the use of physiologic platelet concentrations.
for varying periods of time, the labeled glycogen isolated, and the degree of labeling of outer glycogen branch tier (1-4 linkages) compared with that of the inner core (limit dextrin) obtained after fi-amylase digestion. (This enzyme digests the outer tier, 1-4 linkages.) The specific activity of the outer 14 linkage tier increased up to 2 hr, (Fig. 3) . The specific activity of the inner core increased exponentially as would be expected if new glucosyl units were deposited on already existent glycogen branches, some of which were then converted to 1-6 linkages (followed by [1] [2] [3] [4] 
linkages).
During glycogen degradation. Platelets were incubated for 1 hr at 370C in the presence of glucose--4C in order to label platelet glycogen with isotope. The platelets were then collected, washed in human Ringer, and then reincubated in human Ringer's solution in the absence of glucose-14C for varying time intervals. The labeled glycogen was isolated and treated with and without f-amylase as above. As can be noted from Fig. 4 , the per cent of recently synthesized outer chain (1-4 linkages) tiers, with respect to total synthesized glycogen, decreased with increasing interval of incubation of prelabeled platelets. Of interest was the increase in specific activity of prelabeled platelets (counts per minute per micromole glycogen), with increasing incubation time. The specific activity of total labeled glycogen as well as limit dextrin-labeled glycogen increased with time, the latter increasing considerably at 2 hr. These data indicated that more unlabeled glycogen was being degraded than labeled glycogen (newly synthesized glycogen), suggesting a nonsequential or heterogeneous mode of glycogen depletion.
Glycogen synthetase Fig. 5 (1-4 linkages) during glycogen degradation. Washed platelets were prelabeled for 1 hr by incubation of a 5% suspension in 5 mm glucose, 1 X 100 cpm/ml at 370C. These platelets were then washed, resuspended, and reincubated for varying time intervals. The labeled glycogen was isolated at varying time intervals and analyzed for limit dextrin and outer tier (1-4 linkages Fructose-1,6-diphosphatase activity A fructose-1,6-diphosphatase was present in a 4000 g homogenate of platelets giving a rate of 10.8 Amoles of fructose 6-phosphate/g platelets per hr at 30'C (four experiments with optimal fructose-1,6-diphosphate concentration of 2 mmoles/liter). The rate was linear with increasing homogenate concentration over the range studied and was zero in the absence of fructose-1,6-diphosphate. At the concentration of fructose-1,6-diphosphate present in human platelets (0.087 +0.006 tcmole/g, eight experiments), the rate was 5.2 timole/g per hr, Table IV .
The enzyme was purified 20-fold, had a pH optimum of approximately 7, and had no Mg++ ion requirement. The enzyme was fairly specific for fructose-1,6-diphosphate. The substrates fructose 6-phosphate, glucose 6-phosphate, glucose 1-phosphate, and P-glycerol phosphate, at concentrations of 2 mmoles/liter, gave zero 'Of interest was the observation that citrate incorporation into glycogen was sigmoidal, plateauing at 10 mm extracellular citrate, but then increasing at 20 mmoles/liter and plateauing at 40 mmoles/liter (all data not given). All incubations were maintained at isotonicity by lowering the NaCl concentration. This observation was not further pursued. rates of orthophosphate release after incubation at 300C for 30 min at pH 7.5 in 50 mm Veronal buffer or 50 mM Tris buffer. The Km for fructose-1,6-diphosphate varied between 0.06 and 0.2 mmoles/liter. AMP caused activation of the enzyme, rather than inhibition which has been reported in other tissues (10, (11) (12) (13) , Fig. 6 A, raising Vmax 6-fold. ADP also activated this enzyme, Fig. 6 B, raising Vmax 9-fold. ATP was a potent inhibitor of this enzyme, giving zero rates at physiologic concentrations of ATP, 1-3 mmoles/liter (3), employing similar fructose-1,6-diphosphate concentrations as those shown in Fig. 6 . In the presence of physiologic concentrations of fructose-1,6-diphosphate, AMP, ADP, and ATP (3), the rate was 0.69 Amoles/g per hr, Table IV .
DISCUSSION
Incorporation of glucose-'4C into isolated human platelet glycogen has been reported by Scott (14) and by this laboratory (6) . Our present results both confirm and further document these observations. Human platelets are capable of synthesizing new 1-4 and probable 1-6 glucosyl linkages onto preexistent tiers of branched glycogen polymers via glycogen synthetase which has been measured (and presumably amylo 1-4 > 1-6 transglucosylase which could be inferred, Fig. 3 ). The newly synthesized glycogen is also available to the degradative glycogenolytic enzymes, phosphorylase (which has been described in human platelets, 4, 5, 14) , and probable amylo-1,6 glucosidase (which could be predicted) since The fructose-1,6-diphosphatase activity of human platelets appears unique in its modulation by AMP, ADP, and ATP and lack of requirement for Mg"+ ion. AMP, in contrast to its inhibitory effect on other fructose-1,6-diphosphatases (10, (11) (12) (13) , activates the platelet enzyme. Other specific fructose-1,6-diphosphatases from Escherichia coli and Euglena gracilis (10) have been described which are neither activated nor inhibited by AMP. ADP is also a potent activator, whereas ATP inhibits the enzyme. Inhibition of fructose-1,6-diphosphatase by ATP has also been reported in rat and rabbit liver (18 At physiologic concentration of adenine nucleotide and glucose-6-phosphate, the platelet extract rates of glycogen synthetase (at 370C) and apparent fructose-1,6-diphosphatase (at 30'C) are 7 and 0.69 Amoles g wet weight per hr. These data suggest that fructose-1,6-diphosphatase activity is rate limiting for glycogen synthes's. as it is in other tissues (19, 20) . Human platelet phosphorylase has a rate at 300C of 11 Amoles glucose 1-phosphate/g per hr3 at physiologic concentration (3) of substrates: glycogen and orthophosphate and known effectors: AMP, ATP, and ADP. This would predict a greater potential for glycogen degradation as compared with glycogen synthesis.
Platelets incubated at high concentration (5%) exhibit increased glycogen degradation. As a result, there is less glycogen primer and consequently, a lower rate ' Karpatkin, S., and R. M. Langer. Unpublished data.
of glycogen synthesis than in platelets incubated at physiologic concentration (0.5%). Of interest is a recent observation by Murphy' wherein 24-hr-stored platelet concentrates at 22'C were noted to have 2.3-fold lower glycogen content than similarly stored platelet-rich plasma. Whether the decreased platelet glycogen of platelet concentrates is responsible for the decreased platelet recovery after platelet concentrate transfusions remains to be established.
The reason for increased glycogen degradation with increased platelet concentration remains unexplained. It is not due to platelet aggregation or removal of platelets from plasma. It is probably not a result of releaspe of a platelet metabolite since rates of lactate production are linear at high platelet suspensions (1). It is conceivable that the increased rate of platelet collision, inherent in a higher platelet suspension, may in some way activate glycogen degradation, lactate production, and ATP depletion. It is also conceivable that high platelet suspensions become relatively anaerobic and consequently activate glycogenolysis. It is thus suggested that all previous metabolic data be interpreted with caution, since platelet concentration is a new variable important in the interpretation of these data.
